Results 91 to 100 of about 6,039,132 (349)
Frontiers in Immunology, 2018 Background: The majority of persons diagnosed with multiple sclerosis (MS) experience their first MS symptoms in the reproductive age. Teriflunomide (TFL, Aubagio), was first released in Denmark for relapsing-remitting MS in December 2013.
Johanna Balslev Andersen +4 more
doaj +1 more source
Analysis of Soluble Interleukin‐2 Receptor as a Prognostic Biomarker in NMOSD and MOGAD
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Soluble interleukin‐2 receptor (sIL‐2R) is a biomarker for T cell activity. T cells are involved in neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD) pathogenesis. However, sIL‐2R has so far not been evaluated in these conditions.
Philipp Klyscz +8 more
wiley +1 more source
Nerve Excitability in Asymptomatic Carriers and Amyotrophic Lateral Sclerosis Patients With C9orf72
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective We investigated the effects of C9orf72 mutation carriership on peripheral nerve excitability in asymptomatic individuals from families with a history of C9orf72 amyotrophic lateral sclerosis (ALS) and patients. Methods We included 47 asymptomatic individuals from families with a history of C9orf72 ALS, of whom 23 were carriers (C9 ...
Diederik J. L. Stikvoort García +3 more
wiley +1 more source
Multiple Sclerosis, 2017 Cognitive and motor performance measures are commonly employed in multiple sclerosis (MS) research, particularly when the purpose is to determine the efficacy of treatment.
R. Benedict +5 more
semanticscholar +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To quantify the number and volume of whole brain perivascular spaces (PVS) using a detection and segmentation algorithm in participants with multiple sclerosis (MS) and patients with disorders mimicking MS known to potentially influence PVS, such as cerebrovascular disease.
Elle M. Levit +5 more
wiley +1 more source
Recommendations for cognitive screening and management in multiple sclerosis care
Multiple Sclerosis, 2018 Purpose: To promote understanding of cognitive impairment in multiple sclerosis (MS), recommend optimal screening, monitoring, and treatment strategies, and address barriers to optimal management.
R. Kalb +15 more
semanticscholar +1 more source
The Diverse Neuromuscular Spectrum of VPS13A Disease
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective VPS13A disease (chorea‐acanthocytosis) is a rare neurodegenerative disorder caused by biallelic variants in VPS13A, typically presenting with hyperkinetic movement disorders, while neuromuscular signs are often mild. The aim of the project was to investigate the frequency and severity of neuromuscular impairment in VPS13A disease ...
Anne Buchberger +16 more
wiley +1 more source
Pyoderma gangrenosum in a patient with multiple sclerosis under natalizumab treatment: a case report
BMC NeurologyBackground Pyoderma Gangrenosum (PG) is often considered an immune-mediated disease. Up to 50% of PG cases - a rare, non-infectious inflammatory skin disease characterized by painful necrotic ulcers -are associated with underlying systemic diseases like ...
Kosar Kohandel +4 more
doaj +1 more source
Evaluating Cognitive-Motor Interference in Multiple Sclerosis: A Technology-Based Approach
BioengineeringBackground: People with multiple sclerosis (PwMS) frequently present both cognitive and motor impairments, so it is reasonable to assume they may have difficulties in executing dual-tasks (DT). The aim of the present study is to identify novel technology-
Jessica Podda +3 more
doaj +1 more source